UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2025 Commission File Number: 001-41641

SHL TELEMEDICINE LTD.

(Translation of registrant's name into English)

90 Yigal Alon Street Tel Aviv 67891, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F \boxtimes Form 40-F \square

EXPLANATORY NOTE

On February 4, 2025, SHL Telemedicine Ltd. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1. In the press release, the Company announced that it has appointed Lior Haalman to serve as the Company's new Chief Financial Officer, effective March 1, 2025. Amir Hai, the Company's current Chief Financial Officer, announced his resignation, which will be effective upon Mr. Haalman assuming the position of Chief Financial Officer.

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 9, 2023 (Registration No. 333-272546).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SHL Telemedicine Ltd.

By: <u>/s/ Amir Hai</u> Amir Hai Chief Financial Officer

February 4, 2025



Press release

Ad hoc announcement pursuant to Art. 53 LR

SHL appoints Lior Haalman as new CFO

Tel Aviv / Zurich / New York, February 4, 2025 – SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today that Lior Haalman has been appointed to serve as the company's Chief Financial Officer, starting March 1, 2025, and replacing Amir Hai, who has been with the company for over 3 years.

Lior Haalman is an experienced manager with a proven track record of more than 20 years as a CFO in various public companies in various industries. In his most recent position, he served as CFO of Rekah Pharmaceutical Industry (REKA, TASE). Previously, Lior Haalman spent 9 years as CFO of Infinya (formerly Hadera Paper), where he was a dominant partner in an impressively successful turnaround and value creation process for both, public shareholders, and the controlling shareholder.

Prior to that, Lior Haalman served as CFO of Hot Mobile, during which time he led the sale of MIRS (from Motorola) to HOT company and its transformation into Hot Mobile. From 2000 to 2007, he was a member of the management of Mey Eden and was involved in the expansion of the company's operations in Europe. He holds a bachelor's degree in economics with honors and an MBA, both from Tel Aviv University.

Lior Haalman will be responsible for overseeing all financial operations and reporting, as well as driving the company's continued commitment to financial excellence.

The Board and management team would like to thank Amir Hai for his significant contributions to the Company and wish him all the best in his future endeavors.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).

For more information, please visit our web site at www.shl-telemedicine.com.

Contacts

Fabienne Farner, IRF, Phone: +41 43 244 81 42, farner@irf-reputation.ch

Forward-Looking Statements

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.

SHL Telemedicine 90 Yigal Alon St. Tel-Aviv 6789132, Israel T: +972.3.5612212 F: +972.3.6242414 www.Shl-Telemedicine.com